How many clinical trials are tracked of talimogene laherparepvec?

18 trials are tracked, 0 with published results.

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine Orthopedics & Sports Medicine OB/GYN & Women's Health Radiology & Imaging Genetics & Precision Medicine Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Hematology Urology Ophthalmology Dermatology Emergency Medicine Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Questions

Text Size

talimogene laherparepvec

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of talimogene laherparepvec

18 trials tracked of talimogene laherparepvec: 2 in phase 3 or 4.

18Trials tracked

2Phase 3 & 4

0Recruiting

0With published results

Phase distribution

Phase 3 2 Phase 2 10 Phase 1 6

Phase 3 Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma Completed
Phase 3 An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma Completed
Phase 2 Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Completed
Phase 2 Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma Completed
Phase 2 Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma Completed
Phase 2 TVEC and Preop Radiation for Sarcoma (4 ml Dose) Completed

Show 12 more trials

Phase 2 Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611 Completed
Phase 2 Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma Completed
Phase 2 Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07). Completed
Phase 2 Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec Completed
Phase 2 An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016) Completed
Phase 2 A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma Completed
Phase 1 Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases Completed
Phase 1 Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies Completed
Phase 1 Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors Completed
Phase 1 Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma Completed
Phase 1 Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137) Completed
Phase 1 Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer Completed

Showing the 18 most-cited and recently-updated of 18 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.